Drugs / K-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02720666 | Jan → Dec 2016 | malignant pancreatic neoplasm | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04183478 | Sep 2017 → Mar 2021 | malignant pancreatic neoplasm | RenJi Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04183478 ↗ |
| Modality | Other / unclassified | “K-001 is an antitumor active substance (peptidoglycan)” NCT04183478 ↗ |
| Route | Oral | “K-001 is an oral antitumor drug made from active ingredients of marine microorganisms.” PMID 34098895 ↗ Jun 2021 |